Stocktoria
AXIM BIOTECHNOLOGIES, INC. AXIM
OTC · stock · Pharmaceutical Preparations · website · IPO 2013-04-09
AXIM BIOTECHNOLOGIES, INC. financials (annual, from 10-K)
Bars are annual figures from 2014 to 2023; red bars are negative (a loss or cash outflow).
| Metric | FY2023 | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39,518 | $7,397 | $8,875 | $60,460 | $195,614 | $47,573 | $47,059 | $49,139 | $0 | $85,050 |
| Gross profit | — | — | — | — | $187,103 | $4,716 | -$107,071 | -$1,248 | $0 | — |
| R&D expense | $125,496 | $20,336 | $153,697 | $284,869 | $2.1M | $1.4M | $235,579 | $571,455 | $0 | — |
| SG&A expense | $2.2M | $590,940 | $4.1M | $5.7M | — | — | $3.4M | $9.5M | $505,729 | — |
| Operating income | -$2.8M | -$710,634 | -$4.7M | -$14.0M | -$5.0M | -$3.1M | -$3.8M | -$10.0M | -$505,729 | — |
| Interest expense | — | $57,839 | — | — | $456,063 | $315,013 | $275,734 | $43,221 | $32,522 | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$8.1M | -$2.8M | -$6.2M | -$16.0M | -$6.8M | -$4.2M | -$5.8M | -$10.1M | -$582,947 | -$161,403 |
| EPS (diluted) | $-0.04 | $-0.01 | $-0.04 | $0.12 | — | — | — | — | — | $0.00 |
| Operating cash flow | -$1.0M | — | -$2.0M | -$2.5M | -$4.8M | -$3.1M | -$1.3M | -$1.5M | -$348,999 | $113,002 |
| Free cash flow | -$1.0M | — | -$2.1M | -$2.5M | — | — | -$1.3M | -$1.5M | -$348,999 | — |
| Cash & equivalents | — | $53,542 | $47,282 | $452,963 | $1.8M | $2.1M | $713,346 | $134,170 | $661,128 | $4,838 |
| Inventory | — | — | — | $20,089 | $9,797 | $8,765 | $38,446 | $200,784 | $0 | — |
| Total assets | $4.1M | $4.0M | $4.2M | $5.3M | $2.1M | $2.2M | $1.4M | $1.3M | $738,457 | $4,838 |
| Total liabilities | $11.8M | $10.2M | $9.0M | $7.7M | $8.2M | $8.5M | $3.8M | $3.0M | $1.3M | — |
| Shareholders' equity | -$7.7M | -$6.2M | -$4.8M | -$2.3M | -$6.1M | -$6.3M | -$2.4M | -$1.7M | -$580,723 | -$50,162 |
Growth · year-over-year · Revenue CAGR -8.2%
| Metric | FY2023 | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +434.2% | -16.7% | -85.3% | -69.1% | +311.2% | +1.1% | -4.2% | — | -100.0% | +9.7% |
| EPS growth | — | — | -133.3% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001514946 · US · as of 2023-12-31. facts plus Stocktoria's own computed scores — not investment advice.